Rhythm Pharmaceuticals In... (RYTM)

Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmel...

Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.

Rhythm Pharmaceuticals (RYTM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...

Rhythm Pharmaceuticals said on Monday that its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants David Connolly – Investor Relations and Corporate Communications David Me...

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.70 per share a year ago.

Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on Rhy...

The consensus price target hints at a 26.4% upside potential for Rhythm Pharmaceuticals (RYTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...

Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be m...